The addition of long-acting beta-agonists to inhaled corticosteroids in asthma

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 1, 2011, Pages 23-28

  Sears, Malcolm R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

add on therapy; asthma; inhaled corticosteroids; long acting beta agonists; safety

Indexed keywords

CORTICOSTEROID; FLUTICASONE; FORMOTEROL; PLACEBO; SALMETEROL;

ARTICLE; ASTHMA; CHILD; COCHRANE LIBRARY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS (TOPIC); QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 78650510479     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328341004c     Document Type: Article

References (42)

1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-178.
2. Prenner BM. Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. Curr Opin Pulm Med 2008; 14:57-63.
3. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993;306:1034-1037.
4. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-74.
5. Nelson HS, Weiss ST, Bleecker ER, etal., and the SMART study group. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
6. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting p-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-912.
7. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362:1169-1171.
8. Fanta CH. Asthma. N Engl J Med 2009; 360:1002-1014.
9. Black JL, Oliver BGG, Roth M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting p-agonists. Chest 2009; 136:1095-1100
10. Sindi A, Todd DC, Nair P. Antiinflammatory effects of long-acting p#inf#2#/inf#-agonists in patients with asthma. A systematic review and metaanalysis. Chest 2009; 136:145-154.
11. Greening AP, Wind P, Northfield M, ShawG. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-224.
12. Woolcock A, Lundback BO, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488.
13. Pauwels RA, Lofdahl C-G, Postma DS, etal. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-1411.
14. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, etal. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397.
15. Lemanske RF, Sorkness CA, Mauger EA, etal. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. A randomized controlled trial. JAMA 2001; 285:2594-2603.
16. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol and airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924-930.
17. Murphy S, Roberts R. 'Black-box' 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006; 117:34-39.
18. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events [review]. Cochrane Database Syst Rev 2008; Jul 16 (3):CD006363.
19. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events [review]. Cochrane Database Syst Rev 2008; Oct 8 (4):CD006923.
20. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008; 149:33-42.
21. Jaeschke R, O'Byrne PM, Mezja F, et al. The safety of long-acting p-agonists among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178:1009-1016.
22. Jaeschke R, O'Byrne PM, Nair P, et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and metaanalysis. Pol Arch Med Wewn 2008; 118:627-635.
23. RodrigoGJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 2009; 22:9-19.
24. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events [review]. Cochrane Database Syst Rev 2009; Jul 8 (3):CD006922.
25. Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med 2010; 123:322-328.
26. Levenson M. Long-acting beta-agonists and adverse asthma events metaanalysis. Statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee, 10-11 December 2008. http://www.fda.gov/ohrms/dockets/ac/cder08.html#PulmonaryAllergy.
27. Wechsler ME, Lehman E, Lazarus SC, et al. p-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
28. Basu K, Palmer CNA, Tavendale R, et al. Adrenergic p#inf#2#/inf#-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 2009; 124:1188-1194.
29. Bleecker ER, Nelson HS, Kraft M, et al. p#inf#2#/inf#-Receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181:676-687.
30. Thomas M, von Ziegenweidt J, Lee AJ, Price D. High-dose inhaled corticosteroids versus add-on long-acting p-agonists in asthma: An observational study. J Allergy Clin Immunol 2009; 123:116-121.
31. Sears MR. Step-up therapy in uncontrolled asthma: choices and outcomes. J Allergy Clin Immunol 2009; 123:122-123.
32. Ducharme FM, Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma [review]. Cochrane Database Syst Rev 2010; Apr 14 (4):CD005533.
33. Renzi PM, Howard LA, Ortega HG, et al. Low-dose fluticasone propionate with and without salmeterol in steroid-nä?ve patients with mild, uncontrolled asthma. Respir Med 2010; 104:510-517.
34. Seale JP, Jenkins C, Wood-Baker R, Neville AM, on behalf of the Asthma Management Advisory Board. Benefits of fixed-dose combination therapy with inhaled corticosteroids and long-acting bronchodilators as initial maintenance therapy in the management of asthma. Respirology 2009; 14:224-229.
35. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-na?̈ve adults and children [review]. Cochrane Database Syst Rev 2009; Oct 7 (4):CD005307.
36. De Blic J, Ogorodova L, Klink R, etal. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009; 220:763-771.
37. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children [review]. Cochrane Database Syst Rev 2009; Jul 8 (3):CD007949.
38. Lemanske RF, Masuger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975-985.
39. Von Mutius E, Drazen JM. Choosing asthma step-up care. N Engl J Med 2010; 362:1042-1043.
40. Reddel HK, Gibson PG, Peters MJ, et al. Down-titration from high-dose combination therapy in asthma: removal of long-acting p#inf#2#/inf#-agonist. Respir Med 2010; 104:1110-1120.
41. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009; 360:1671-1672.
42. Sears MR. Safety of long-acting p-agonists. Are new data really required? Chest 2009; 136:604-607.